SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19

NCT05629962 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2285

Enrollment

INDUSTRY

Sponsor class

Conditions

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection)
COVID-19

Interventions

DRUG: Bemnifosbuvir (BEM)
DRUG: Placebo

Sponsor

Atea Pharmaceuticals, Inc.